CRMD Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 10.59%. CorMedix, Inc.'s return on equity of 95.25% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 55.87%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.33%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. CorMedix, Inc.'s net income of $108.6M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.94x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 4.10x versus 2.01x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arcutis Biotherapeutics, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 7.47%. CorMedix, Inc.'s return on equity of 95.25% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 55.87%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 7.9%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. CorMedix, Inc.'s net income of $108.6M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.94x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 4.10x versus 11.83x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Castle Biosciences, Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of -0.6%. CorMedix, Inc.'s return on equity of 95.25% beat Castle Biosciences, Inc.'s return on equity of -2.71%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 55.87%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $40.38 which suggests that it could grow by 0.71%. Given that CorMedix, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Castle Biosciences, Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.213%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. CorMedix, Inc.'s net income of $108.6M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.94x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 4.10x versus 3.43x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 49.9% compared to CorMedix, Inc.'s net margin of 21.32%. CorMedix, Inc.'s return on equity of 95.25% beat Pfizer Inc.'s return on equity of 10.84%.

CorMedix, Inc. has a consensus price target of $19.00, signalling upside risk potential of 55.87%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that CorMedix, Inc. has higher upside potential than Pfizer Inc., analysts believe CorMedix, Inc. is more attractive than Pfizer Inc..

CorMedix, Inc. has a beta of 1.322, which suggesting that the stock is 32.155% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

CorMedix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. CorMedix, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

CorMedix, Inc. quarterly revenues are $104.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. CorMedix, Inc.'s net income of $108.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, CorMedix, Inc.'s price-to-earnings ratio is 5.94x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CorMedix, Inc. is 4.10x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.